---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-24-000009"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T00:41:28.491623+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q4 adj EPS flat YoY at $1.83; FY24 adj EPS guidance $7.50-$7.75 vs $8.08 in FY23

## Summary
- Q4 net sales $732.0M (+3.3% YoY); full-year net sales $2.950B (+2.2% YoY).
- Q4 reported EPS $1.83 (+34.6% YoY); full-year reported EPS $7.88 (+1.9% YoY).
- FY24 guidance: net sales $3.000B-$3.025B; adjusted EPS $7.50-$7.75; organic sales growth ~2%-3%.
- Proprietary Products organic sales down 0.3% Q4; COVID headwinds cited; excluding COVID, high-single-digit growth.
- FY23 free cash flow $414.5M (down 5.7%); repurchased 1.27M shares for $438.3M at avg $346.34.

## SEC filing metadata
- accession: 0000105770-24-000009
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/wst-20240215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-24-000009
- JSON: https://secwatch.observer/filing/0000105770-24-000009.json
- Plain text: https://secwatch.observer/filing/0000105770-24-000009.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported Full-year 2024 results: revenue in a range of $3.000 billion to $3.025 billion, EPS adjusted-diluted EPS in a range of $7.50 to $7.75. Guidance initiated.
  - Period: Full-year 2024
  - Revenue: in a range of $3.000 billion to $3.025 billion
  - EPS: adjusted-diluted EPS in a range of $7.50 to $7.75
  - Guidance: initiated
  - Result: preliminary results
  source text: The Company is introducing full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and adjusted-diluted EPS in a range of $7.50 to $7.75.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.
  - Period: the fourth-quarter and full-year 2023
  - Revenue: $2.950 billion
  - EPS: $7.88
  - Guidance: reaffirmed
  - Result: reported results
  source text: full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) • Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%. • Fourth-quarter 2023 reported-diluted EPS
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.
  - Period: the fourth-quarter and full-year 2023
  - Revenue: $2.950 billion
  - EPS: $7.88
  - Guidance: reaffirmed
  - Result: reported results
  source text: Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.